

Concerns for Special Patient Populations With MS

Overview

- MS and gender
- Studies suggest gender affects susceptibility and course of MS
- Women: higher prevalence and better overall prognosis than men
 - Possibly due to effect of sex hormones on neurological damage and repair mechanisms, cytokines, BBB, and CNS parenchymal cells
- Gender-specific effects of hormones in MS pathology and therapy response
- MS and age
- Children
- Elderly

BBB=blood-brain barrier; CNS=central nervous system

Tomassini V, Pozzilli C. *Expert Opin Pharmacother.* 2006;7(7):857-868.

Nicot A. *Front Biosci.* 2009;14:4477-4515.

MS in Women: Menses and Menopause

Studies show:

- Estrogens may play an important role in protecting the CNS against inflammation
- Anti-inflammatory action of estrogens occur directly on microglia
- Potential therapeutic use of hormones?
- Premenstrual relapses can occur

MS in Women: Pregnancy

Studies show:

- MS does not affect ability to conceive
- MS does not increase risk of congenital malformations in babies
- Small for gestational age more common
- Deliveries more complicated
- C sections more likely
- Preterm delivery more common
- Symptoms may worsen in pregnancy (eg, mobility, gait, fatigue, urinary symptoms)
- Relapses may decrease in pregnancy but increase postpartum
- Pregnancy does not seem to affect the course of MS
- MS may improve in late pregnancy

NMSS. Reproductive issues in person with multiple sclerosis. Clinical Bulletin, Information for health professionals: www.nationalmssociety.org/pdf/forpros/Pregnancy.pdf; September 21, 2006.

Ferrero S, et al. *Eur J Obstet Gynecol Reprod Biol.* 2004;115(1):3-9.

Chen Y, Lin H. *Mult Scler.* 2009.

Sandberg-Wollheim M, et al. *Neurology.* 2005;65(6):802-806.

MS in Pregnancy, continued

- **Treatment of MS during pregnancy and post-partum**
 - Interferon beta-1a therapy associated with miscarriages, stillbirth, and malformations
 - None of the disease-modifying therapies (DMTs) are recommended in pregnancy
 - Glatiramer acetate has a category B rating in pregnancy
 - Patients usually stop DMTs 1-2 months prior to trying to conceive
 - Relapses during pregnancy can be treated with steroids after first trimester
 - Post-partum relapse can be treated by intravenous immunoglobulin (IVIG) therapy and steroids

Ferrero S, et al. *Eur J Obstet Gynecol Reprod Biol.* 2004;115(1):3-9.

Sandberg-Wollheim M, et al. *Neurology.* 2005;65(6):802-806.

Sellebjerg F, et al. *Eur J Neurol.* 2005;12(12):939-946.

MS in Children: Overview

- **3.5%-5% of 2.5M patients are diagnosed before age 18**
- **Onset as young as 10 months**
- **Many adults with MS report symptoms in childhood**
- **Children are likely under diagnosed**
- **Diagnostic criteria: presence of recurrent neurologic dysfunction involving separate areas of the nervous system and relapses, each lasting at least 24 hours**
- **Hospital for sick children**

MS in Children

RRMS in childhood

- Disease progression may be slower in children
- 50% with onset before age 16 and switch to SPMS after 23 years
- 2.6%-5% PPMS

Considerations...

- Developing brain and spinal cord
- Immature immune system
- Different concerns (school performance, peer relationships, recreation, play)
- Education and support needs differ
- Issues of substitute decision making

MS in Children

Presenting symptoms

- Similar to adults
- Children are more likely to be systemically unwell at onset of disease and exhibit symptoms of encephalopathy (malaise, irritability, low grade fever)

Common presenting symptoms

- Hemiplegia
- Optic neuritis
- Brain stem/cerebellar signs

MS in Children

Symptoms

- Cognitive deficits
- Heat intolerance
- Fatigue
- Depression
- Tremors
- Headache
- Seizures

MS in Children

Treatment challenges

- Parents make treatment decisions
- Young children don't have the capability to understand the rationale for injections and long-term benefits
- Adolescents do not always accept the need for therapy

Treatment challenges

- Long-term steroid use causes growth retardation
- No studies with DMT in children
- DMTs are not FDA approved for pediatric use
- No clinical trials in pediatrics (efficacy, dosing)

Disease-Modifying Therapies

- **Dosing: start at $\frac{1}{4}$ - $\frac{1}{2}$ of the dose and gradually increase to full dose as tolerated**
- **Consider staying at $\frac{1}{2}$ of the dose for children <7 years old**
- **Maximize dose while minimizing side effects—monitor CBC, liver function tests closely**
- **Make the first injection a positive experience**
- **Involve the whole family in teaching**
- **Encourage the participation of the child as much as possible**
- **Use a teaching doll**

Initiating Disease-Modifying Therapies

- Offer choices (manual vs auto-injector)
- Ask the child what would help with coping (eg, sitting on a parent's lap, holding a favorite toy, etc.)
- Consider using a topical anesthetic cream
- Have the parent observe the nurse administering the first injection

Resources for Families

- **National MS Society. Children/teens with MS and their parents' support network website**
 - **National Multiple Sclerosis Society. Keep S'myelin:**
<http://www.nationalmssociety.org/multimedia-library/kids-keep-smyelin/index.aspx>; April 10, 2009.
- **MS World, Inc. Message boards for parent, teens, and children to post messages and share experiences**
 - **(MS World. <http://www.msworld.org/html/>. Accessed April 10, 2009.)**

Special Populations With MS: Elderly

- MS typically diagnosed in the 20-40 age range. It is a chronic debilitating disease but does not typically reduce life expectancy
- Specific issues related to aging with MS: fear of the future related to
 - Loss of mobility
 - Loss of independence
 - Becoming a burden on family
 - Having to move to a nursing home
 - Losing control over future

Elderly

- **Other neurological and non-neurological diseases affecting elderly patients with MS**
 - **Parkinson's**
 - **Stroke**
 - **Heart disease**
 - **Breast cancer**
 - **Diabetes**
 - **Urinary tract infections (UTIs)**
 - **Depression**
 - **Osteoporosis**
 - **Poor nutrition**
 - **Injury due to falls/driving**

Clinical Case: Dorothy

- A 64-year-old woman recently was in an automobile accident that resulted in a fracture of her left hip. She was hospitalized for surgery and monitoring.
- She complained of a headache, and an MRI revealed periventricular lesions in her brain.
- Neurologic examination was positive for sensory loss in both lower extremities, a wide-based ataxic gait, and dystaxia of all extremities.
- Lumbar puncture was positive for oligoclonal banding.
- She was informed she has multiple sclerosis.
- Her medical history was positive for frequent UTIs, osteopenia, and short-term memory loss.
- After inpatient rehabilitation, she comes to your office requesting MS treatment.

What treatments would be appropriate for this patient?

- a. **Rehabilitation services**
- b. **Observation**
- c. **Corticosteroids**
- d. **Neurologic monitoring**

What are the patient's risks at this time?

- a. **Falls**
- b. **Managing her affairs**
- c. **Infections**
- d. **None at this time**

Clinical Case: Steven

- **A 14-year-old male recently diagnosed with multiple sclerosis.**
- **He is at your office very upset, is refusing to take his injectable medication, and wants “out” of the health care system.**
- **His friends are making fun of him. He hates being different.**

What can you do to help?

- a. Suggest counseling for him and his family**
- b. Send him to a support group**
- c. Insist he take his medication to control his MS**
- d. Involve his parents**

What treatments are not indicated for pediatric MS?

- a. DMTs
- b. Corticosteroids
- c. Pain medications
- d. **Chemotherapy**

Clinical Case: Sally

- A 24-year-old woman with a history of MS for 3 years.
- She is 6-months pregnant.
- She presents at your office with vision loss in her left eye. V/A is 20/200.
- No other hard findings on examination.

What should be done first?

- a. Ophthalmology consult
- b. Call her OB/GYN
- c. Obtain an MRI
- d. **All of the above**

Corticosteroids are not indicated when a patient is pregnant.

a. True

b. **False**